Skip to main content
OpenTrials
Completed

NCT Number: NCT03567798

Thrombocytopenia Induced by Chemotherapy

Single blind, randomized, multicentric placebo controlled study to evaluate the efficacy of Study product in patient with Chemotherapy induced thrombocytopenia. The Study is divided into [screening visit (visit 1) > baseline and treatment allocation visit (visit 2) >blood collection (visit 3); treatment compliance visit (visit 4) > blood collection (visit 5) >blood collection (visit 6)>end of study visit (visit 7)].

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

North East Cancer Centre Hospital and research Institute

Guwahati, Assam, 781023, India

About this study

UPLAT® (Carica papaya leaf Extract + Tinospora cardifolia Extract), is an orally administered dietary supplement for management of thrombocytopenia. Manufactured bySanat Products Ltd.

Throughout study, it will be designated as product A to maintain study blindness at subject end.

Placebo Throughout study, it will be designated as product B to maintain study blindness at subject end.

Single blind, randomized, multicentric placebo controlled study to evaluate the efficacy of Study product in patient with Chemotherapy induced thrombocytopenia. The Study is divided into [screening visit (visit 1) > baseline and treatment allocation visit (visit 2) >blood collection (visit 3); treatment compliance visit (visit 4) > blood collection (visit 5) >blood collection (visit 6)>end of study visit (visit 7)].

Dose regimen After meeting the inclusion criteria subject will take 4 units daily (2 in morning and 2 in evening) for 10 days. Patients will be called on Day5th, 10th and 15thfor the Complete blood count (Central lab).

Total blood loss Approximately 8-12 mL

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female aged between 18-55 years.
  • Subjects must sign with date an informed consent prior to any evaluation and participation in the trial.
  • Patients who were confirmed solid tumour and received at least one cycle of chemotherapy prior to screening visit.
  • Patients with a platelet counts between > 20000 and < 150,000/ml at the time of screening.

Exclusion criteria

  • Planning to receive any type of surgery.
  • Pregnant or lactating women.
  • Patients with platelet count less than 20000/ml.
  • Patients with thrombocytopenia presenting with active bleeding.
  • Patients who have received blood or blood product transfusion during the current illness or during past one week.
  • Patients with thrombocytopenia purpura (ITP) leukemia, hemophilia or bleeding diathesis.
  • Participation in another trial with another investigational product

Treatment and study plan

UPLAT

Dietary Supplement

Carica papaya leaf Extract + Tinospora cardifolia Extract

Placebo

Other

Placebo

Primary outcomes

  1. Increase in the platelet counts from baseline levels to the end of therapy.

    Time frame: Day 15

    Increase in the platelet counts from baseline levels to the end

    of therapy.

Sponsors and collaborators

Lead sponsor

Socrates School Of Health

Industry

Registry information

Official study title

A Post Marketing Randomized Placebo Controlled Study to Evaluate the Efficacy of Study Product UPLAT® (Carica Papaya Leaf Extract + Tinospora Cardifolia Extract) in the Cancer Patients With Thrombocytopenia Induced by Chemotherapy

Acronym: papayaleaf

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Jun 26, 2018
Registry last updated
Jun 27, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.